SELECT was a large study focused on obesity and cardiovascular disease in people without type 2 diabetes, but it included kidney outcomes as a secondary end point. The data showed that semaglutide ...
Previously hailed – or derided – as weight-loss aids for the rich and famous, drugs such as Mounjaro, Wegovy and Ozempic took on a far more expansive role in 2025. No longer just considered treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results